Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

The announcement came in the build-up to an R&D presentation to investors that will be held in New York later today ... come under pressure. Sanofi CEO Paul Hudson All eyes are now on today ...

Sanofi ends speculation, confirms it will spend €1.3B to build new insulin plant in Germany More recently, Sanofi last month said it would shell out 1.3 billion euros ($1.4 billion) to build a ...

French healthcare company Sanofi has decided to halt work on its once praised breast cancer medication amcenestrant after a second failed clinical trial. A possible new coronavirus vaccine ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For ... The deal will be funded by existing cash and new committed bank debt facilities. Net debt is expected to be approximately ...

Robert is currently chief digital officer at the cruise line firm Viking Cruises and will join Sanofi on 15th June. His brief is to drive Sanofi’s digital, data and technology strategy ...

NEW YORK, Sept 23 (Reuters) - Sanofi's (SASY.PA), opens new tab chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new ...

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines.